FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 06/2024”.
The Monitor is a month-to-month printed overview of enterprise capital traits within the European Healthcare & Life Sciences sector.
As of the top of June 2025 we recognized the next present VC traits in Europe:
- Whole Healthcare & Life Sciences funding quantity reached EUR 6,109m
- Funding quantity is now 33% greater than final yr, a pointy enhance in funding quantity vs. 2024
- Biotech/Pharma obtained 40% of the whole funding quantity (EUR 2,426m) with metabolic issues (together with Diabetes, Weight problems) being the main indication (23%)
- In June, Juvenescence (Eire) secured the highest transaction quantity with EUR 132m, adopted by SpliceBio (Switzerland) with EUR 119m and Draig Therapeutics (Nice Britain) with EUR 103m
- GV (United States) is essentially the most energetic investor (by deal quantity in 2025), adopted by Alphabet (United States) and Thrive Capital (United States)
To entry the total report, please click on right here.
By Mathias Klozenbücher and Johannes Hyperlink